Updated time: 2022-09-01 14:05:57
12A-1061103
TW I697499、JP 特許第7101252
We invent a method of diagnosis for peripheral neuropathy, in which the method is to use antibody to detect the expression of a sensory neuron-specific protein (SNSP) in biofluid. The invention is based on our discovery that sensory neuron-associated proteins often shed-off from growth cones during axon degeneration and/or regeneration in the context of peripheral neuropathy. We have thus generated antibodies targeting on SNAP and demonstrated the detection of the protein in cerebrospinal fluid in mouse models of multiple sclerosis, chemotherapy-induced peripheral neuropathy, and chronic constriction injury of sciatic nerve. Accordingly, we have successfully generated a hybridoma to produce monoclonal antibody specific for the human SNSP, so that it can be used for diagnosis of peripheral neuropathy.
The monoclonal antibody against SNSP can be used for diagnosis of peripheral neuropathy, especially for painful neuropathy associated with isolectin B4-positive nociceptors. The monoclonal antibody is suitable for development of methods and/or kits to detect the expression of SNSP in biofluids (e.g., cerebrospinal fluid, serum, ascites, etc.) patients with multiple sclerosis, chemotherapy-induced peripheral neuropathy, sciatica, idiopathic c-fiber neuropathy, etc.
A molecular marker specific for peripheral neuropathy.
In comparison with skin biopsy, the new method provides information of molecular target – the sensory protein SNSP and neuron-subtype specificity for neuropathy associated with isolectin B4-positive nociceptors.
Chih-Cheng Chen、Yu-Chia Chuang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Biomarkers and methods specific for diagnosis of peripheral neuropathy